Business · 02/10/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for BYETTA Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for Pfizer's BYETTA patent extension, following a formal submission to the US Department of Commerce, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →